Susan ALTSCHULLER - Jun 1, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Chief Financial Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Jun 1, 2023
Transactions value $
$0
Form type
4
Date filed
6/5/2023, 08:15 PM
Previous filing
May 19, 2023
Next filing
Nov 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +124K $0.00 124K Jun 1, 2023 Common Stock 124K $32.55 Direct F1
transaction CERE Restricted Stock Units Award $0 +30.7K $0.00 30.7K Jun 1, 2023 Common Stock 30.7K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on June 1, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3 The RSUs vest in four equal annual installments on each of June 1, 2024, June 1, 2025, June 1, 2026 and June 1, 2027, subject to the Reporting Person's continued service on each such vesting date.